Parth Desai

Parth Desai

Auto-generated profile, based on publicly available information

Parth Desai

Fox Chase Cancer Center, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
LPLőrinc Sándor Pongor
Lőrinc Sándor Pongor
CSChristopher William Schultz
Christopher William Schultz
LRLorenzo Rinaldi
Lorenzo Rinaldi
DWDarawalee Wangsa
Darawalee Wangsa
CRChristophe Redon
Christophe Redon
ATAnish Thomas
Anish Thomas
Small-cell lung cancer (SCLC) is an aggressive neuroendocrine lung cancer. Oncogenic MYC amplifications drive SCLC heterogeneity, but the genetic mechanisms of MYC amplification and phenotypic plasticity, characterized by neuroendocrine and nonneuroendocrine cell states, are not known. Here, we integrate whole-genome sequencing, long-range optical mapping, single-cell DNA sequencing, and fluorescence in situ hybridization to find extrachromosomal DNA (ecDNA) as a primary source of SCLC oncogene amplifications and driver fusions. ecDNAs bring to proximity enhancer elements and oncogenes, creating SCLC transcription-amplifying units, driving exceptionally high MYC gene dosage. We demonstrate that cell-free nucleosome profiling can noninvasively detect ecDNA amplifications in plasma, facilitating its genome-wide interrogation in SCLC and other cancers. Altogether, our work provides the first comprehensive map of SCLC ecDNA and describes a new mechanism that governs MYC-driven SCLC heterogeneity. ecDNA-enabled transcriptional flexibility may explain the significantly worse survival outcomes of SCLC harboring complex ecDNA amplifications. Significance: MYC drives SCLC progression, but the genetic basis of MYC-driven SCLC evolution is unknown. Using SCLC as a paradigm, we report how ecDNA amplifications function as MYC-amplifying units, fostering tumor plasticity and a high degree of tumor heterogeneity. This article is highlighted in the In This Issue feature, p. 799

1 October 2015 in Histopathology
Verified
Journal Article
Closed access
PDF file
SLShaoying Li
Shaoying Li
PDParth Desai
Parth Desai
PLPei Lin
Pei Lin
CYC Cameron Yin
C Cameron Yin
GTGuilin Tang
Guilin Tang
LML Jeffrey Medeiros
L Jeffrey Medeiros

1 February 2017 in Laboratory Investigation
Verified
Journal Article
Closed access
XWXuan J Wang
Xuan J Wang
LML Jeffrey Medeiros
L Jeffrey Medeiros
CBCarlos E Bueso-Ramos
Carlos E Bueso-Ramos
GTGuilin Tang
Guilin Tang
SWSa Wang
Sa Wang
SLShaoying Li
Shaoying Li

31 December 2016 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
BTBeenu Thakral
Beenu Thakral
LML. Jeffrey Medeiros
L. Jeffrey Medeiros
PDParth Desai
Parth Desai
PLPei Lin
Pei Lin
CYC. Cameron Yin
C. Cameron Yin
SLShaoying Li
Shaoying Li

1 December 2017 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
AQAndrés E Quesada
Andrés E Quesada
LML Jeffrey Medeiros
L Jeffrey Medeiros
PDParth A Desai
Parth A Desai
PLPei Lin
Pei Lin
JWJason R Westin
Jason R Westin
SLShaoying Li
Shaoying Li

8 May 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MAMelissa L. Abel
Melissa L. Abel
NTNobuyuki Takahashi
Nobuyuki Takahashi
CPCody Peer
Cody Peer
CRChristophe Redon
Christophe Redon
SNSamantha Nichols
Samantha Nichols
ATAnish Thomas
Anish Thomas
Purpose: Despite promising preclinical studies, toxicities have precluded combinations of chemotherapy and DNA damage response (DDR) inhibitors. We hypothesized that tumor-targeted chemotherapy delivery might enable clinical translation of such combinations. Patients and Methods: In a phase I trial, we combined sacituzumab govitecan, antibody–drug conjugate (ADC) that delivers topoisomerase-1 inhibitor SN-38 to tumors expressing Trop-2, with ataxia telangiectasia and Rad3-related (ATR) inhibitor berzosertib. Twelve patients were enrolled across three dose levels. Results: Treatment was well tolerated, with improved safety over conventional chemotherapy-based combinations, allowing escalation to the highest dose. No dose-limiting toxicities or clinically relevant ≥grade 4 adverse events occurred. Tumor regressions were observed in 2 patients with neuroendocrine prostate cancer, and a patient with small cell lung cancer transformed from EGFR-mutant non–small cell lung cancer. Conclusions: ADC-based delivery of cytotoxic payloads represents a new paradigm to increase efficacy of DDR inhibitors. See related commentary by Berg and Choudhury, p. 3557